Re-evaluating DAA therapy in active hepatocellular carcinoma: from controversy to clinical considerations
{{output}}
Direct-acting antiviral (DAA) therapy has brought a revolution to the management of chronic hepatitis C virus (HCV) infection, but its role in patients with active hepatocellular carcinoma (HCC) remains controversial. Early observations suggested a high rate o... ...
